In the Amgen v. Hospira litigation, Amgen has filed a Notice of Appeal relating to Judge Andrew’s oral ruling denying Amgen’s request to compel Hospira to produce certain manufacturing information related to its Epogen® (epoetin alfa) biosimilar product. We previously covered the discovery dispute in detail here.
The appeal was placed on the Federal Circuit’s docket on June 7, and Amgen’s appeal brief is currently due on August 8.
Big Molecule Watch will continue to keep you updated with the status of the appeal and the district court litigation.
